The Pharma Data

APRIL 7, 2021

months with chemotherapy (HR: 0.43; 95% CI: 0.35-0.54; months (HR: 0.51; 95% CI: 0.41-0.62; The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. Medicines targeting these receptors therefore are not typically effective in treating TNBC. months from 1.7

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

SEPTEMBER 2, 2021

AstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021. Lead author. Abstract title. Presentation details. Immuno-Oncology.

Trials 52

Trials Medicine Antibody Clinical Trials 52

The Pharma Data

NOVEMBER 24, 2020

Results from the ILLUMINATE-A and ILLUMINATE-B studies demonstrate that Oxlumo addresses the underlying pathophysiology of PH1 in adults, children and infants, and we believe this newly approved medicine has the potential to change the course of this progressive disease,” said Akshay Vaishnaw, M.D., 0.514 mmol/24 hr/1.73

FDA Approval 52

FDA Approval Production RNA Medicine 52

The Pharma Data

APRIL 14, 2021

Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, an oncologist at New York-Presbyterian/Weill Cornell Medical Center and principal investigator of the TROPHY study. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52